Compare Apple Inc (AAPL) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance

Apple (AAPL) trades at $314.13, up 0.47% today, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $416.16B and net income of $112.01B, beating earnings estimates in recent quarters. Analyst consensus is bullish with a $329.62 price target, though valuation ratios like P/E of 37.61 and P/B of 42.85 suggest premium pricing. Recent news highlights AI potential via a partnership with Alphabet's Gemini and ongoing retail adjustments.

Outlook remains positive driven by earnings growth and AI integration, but risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny. The stock offers stability with consistent cash flow and dividend payments, yet investors should weigh premium multiples against growth sustainability in a challenging macro environment.

AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.

The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.